Plasma Levels and Tissue Expression of Selected Cytokines, Metalloproteinases and Tissue Inhibitors in Patients With Cervical Cancer.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 15 09 2019
revised: 10 10 2019
accepted: 14 10 2019
entrez: 10 11 2019
pubmed: 11 11 2019
medline: 15 11 2019
Statut: ppublish

Résumé

Cytokines, metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) take part in many processes involved in tumor progression and invasion such as degradation of the extracellular matrix, influence on immune cells associated with tumor tissue, and angiogenesis. Thus, the aim of this study was to compare the concentration of plasma levels and tissue expression of macrophage colony-stimulating factor (M-CSF), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and MMP9, and their tissue inhibitors TIMP1 and TIMP2 in patients with cervical cancer, patients with high-grade cervical intraepithelial dysplasia (CIN3) and patients with ectropion. Concentration and expression of all tested parameters was measured in serum with enzyme-linked immunosorbent assay (ELISA) and in tissue with immunohistochemistry method. The epithelial expression of M-CSF and TIMP1 in cancer tissue was much stronger as compared to that in ectropion and CIN3. In the case of MMP2, lack of or weak expression in epithelial cells was observed in all tested groups. Our studies showed statistical differences of tested parameters in tissue expression and in plasma concentrations in patients with cervical cancer, patients with CIN3 and patients with ectropion. Moreover, data revealed positive correlation between plasma level and cervical cancer cell expression of VEGF. Our findings indicate a potential role of all the proteins tested here in cervical cancer diagnosis, especially VEGF. However, further studies will show whether they play a role in the progression of cancerous changes in epithelial tissue of the cervix.

Sections du résumé

BACKGROUND BACKGROUND
Cytokines, metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) take part in many processes involved in tumor progression and invasion such as degradation of the extracellular matrix, influence on immune cells associated with tumor tissue, and angiogenesis. Thus, the aim of this study was to compare the concentration of plasma levels and tissue expression of macrophage colony-stimulating factor (M-CSF), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP)-2 and MMP9, and their tissue inhibitors TIMP1 and TIMP2 in patients with cervical cancer, patients with high-grade cervical intraepithelial dysplasia (CIN3) and patients with ectropion.
PATIENTS AND METHODS METHODS
Concentration and expression of all tested parameters was measured in serum with enzyme-linked immunosorbent assay (ELISA) and in tissue with immunohistochemistry method.
RESULTS RESULTS
The epithelial expression of M-CSF and TIMP1 in cancer tissue was much stronger as compared to that in ectropion and CIN3. In the case of MMP2, lack of or weak expression in epithelial cells was observed in all tested groups. Our studies showed statistical differences of tested parameters in tissue expression and in plasma concentrations in patients with cervical cancer, patients with CIN3 and patients with ectropion. Moreover, data revealed positive correlation between plasma level and cervical cancer cell expression of VEGF.
CONCLUSION CONCLUSIONS
Our findings indicate a potential role of all the proteins tested here in cervical cancer diagnosis, especially VEGF. However, further studies will show whether they play a role in the progression of cancerous changes in epithelial tissue of the cervix.

Identifiants

pubmed: 31704874
pii: 39/11/6403
doi: 10.21873/anticanres.13854
doi:

Substances chimiques

CSF1 protein, human 0
Cytokines 0
TIMP1 protein, human 0
TIMP2 protein, human 0
Tissue Inhibitor of Metalloproteinase-1 0
Tissue Inhibitor of Metalloproteinases 0
VEGFA protein, human 0
Vascular Endothelial Growth Factor A 0
Tissue Inhibitor of Metalloproteinase-2 127497-59-0
Macrophage Colony-Stimulating Factor 81627-83-0
Metalloproteases EC 3.4.-
Matrix Metalloproteinase 2 EC 3.4.24.24
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6403-6412

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Iwona Sidorkiewicz (I)

Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland iwona.sidorkiewicz@umb.edu.pl.

Barbara Piskór (B)

Department of Aesthetic Medicine, Medical University of Bialystok, Bialystok, Poland.

Emilia Dąbrowska (E)

Department of Aesthetic Medicine, Medical University of Bialystok, Bialystok, Poland.

Katarzyna Guzińska-Ustymowicz (K)

Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland.

Anna Pryczynicz (A)

Department of General Pathomorphology, Medical University of Bialystok, Bialystok, Poland.

Monika Zbucka-Krętowska (M)

Department of Reproduction and Gynecological Endocrinology, Bialystok, Poland.

Sławomir Ławicki (S)

Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, Bialystok, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH